![Table 2 from Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. | Semantic Scholar Table 2 from Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/23105e70b26fe79814af246dbc3031cea8381c34/2-Table2-1.png)
Table 2 from Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. | Semantic Scholar
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States | PLOS ONE
![Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-06005-0/MediaObjects/41598_2022_6005_Fig1_HTML.png)
Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports
![Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-022-06005-0/MediaObjects/41598_2022_6005_Fig2_HTML.png)
Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea | Scientific Reports
![The making of the one pill—Developing single tablet regimens for HIV and for HCV - Taiyin Yang, Reza Oliyai, Kenneth M Kent, 2022 The making of the one pill—Developing single tablet regimens for HIV and for HCV - Taiyin Yang, Reza Oliyai, Kenneth M Kent, 2022](https://journals.sagepub.com/cms/10.1177/13596535211067606/asset/images/large/10.1177_13596535211067606-fig3.jpeg)
The making of the one pill—Developing single tablet regimens for HIV and for HCV - Taiyin Yang, Reza Oliyai, Kenneth M Kent, 2022
![Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries | AIDS Research and Therapy | Full Text Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries | AIDS Research and Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12981-020-00268-1/MediaObjects/12981_2020_268_Fig2_HTML.png)
Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries | AIDS Research and Therapy | Full Text
![Isolated Package of Stribild Treatment Editorial Stock Image - Image of sickness, prescription: 183159249 Isolated Package of Stribild Treatment Editorial Stock Image - Image of sickness, prescription: 183159249](https://thumbs.dreamstime.com/z/prague-czech-republic-april-stribild-single-tablet-regimen-treatment-human-immunodeficiency-virus-hiv-infection-183159249.jpg)
Isolated Package of Stribild Treatment Editorial Stock Image - Image of sickness, prescription: 183159249
![STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes](https://www.natap.org/2013/images/071013/071013-2/IAS2.gif)
STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes
![US FDA approves ViiV Healthcare's Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults | BioSpace US FDA approves ViiV Healthcare's Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults | BioSpace](https://mms.businesswire.com/media/20190408005806/en/714550/4/DOVA0028_HR_F_%282%29.jpg)
US FDA approves ViiV Healthcare's Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults | BioSpace
台灣愛滋病學會- 新的用藥規範開始了,應部分臉友要求再分享:藥學人生- Pharmalife· 2019年HIV 單藥錠(single tablet regimen; STR) 小整理——————————————— 文章連結:http://bit.ly/31YXWgs
![TriiAdd study looks to improve adherence with a single pill per day | Research | CIHR Canadian HIV Trials Network TriiAdd study looks to improve adherence with a single pill per day | Research | CIHR Canadian HIV Trials Network](https://www.hivnet.ubc.ca/wp-content/uploads/2015/04/ctn286header.jpg)